Articles tagged with Thyroid Cancer
Researchers found that routine removal of neck lymph nodes during initial thyroid surgery for papillary thyroid cancer may lead to lower disease recurrence rates and lower levels of thyroglobulin, a thyroid tumor marker. This procedure may reduce the need for further surgeries in the critical central area of the neck.
Researchers have found that thyroid cancers with BRAF mutations are exquisitely dependent on the BRAF signaling pathway for viability. Treatments targeting this pathway can restore radioiodine incorporation, suggesting a new therapeutic approach for patients with BRAF-positive papillary thyroid carcinomas.
Researchers identify a new way to boost the aged immune response to flu viruses by inhibiting PGD2. They also discover that targeting BRAF in thyroid cancers could restore the efficacy of RAI therapy. Additionally, exploring EGFR as a therapeutic target for Cushing disease may provide new treatment options.
Thyroid dysfunction is a common side effect of antineoplastic agents in 20-50% of cancer patients, causing fatigue, weakness, and depression. Researchers recommend screening for thyroid disease and monitoring of thyroid function tests to improve patient quality of life.
A study aims to utilize Galectin-3 and HBME-1 proteins as biomarkers for thyroid cancer diagnosis, enabling earlier detection and reducing surgical interventions. The research has the potential to improve patient outcomes by accurately identifying patients at risk of cancer.
A study published in The Lancet found that World Trade Center-exposed New York City male firefighters are 19% more likely to have cancer compared to their non-exposed colleagues, as well as a comparable sample of the general population. The study analyzed data from 9853 male firefighters and found increased cancer incidence rates in WT...
A new study from the University of Michigan Comprehensive Cancer Center found that thyroid cancer treatment varies greatly depending on where patients receive care. Radioactive iodine treatment is being used more frequently overall, but hospital factors play a significant role in its use, accounting for 29% of variation.
A study found a significant increase in use of radioactive iodine after surgery for well-differentiated thyroid cancer, with variation in practice patterns among hospitals. The use was more common in younger patients without comorbidities and those with lower tumor stages.
A Mayo Clinic study has found that a mutant gene thought to accelerate tumor growth actually inhibits the spread of malignant cells, showing promise for novel cancer therapies. The PAX8/PPARγ fusion protein functions as a tumor suppressor by upregulating anti-tumor agents.
Georgia Health Sciences University surgeons developed a robotic facelift incision technique for removing diseased thyroid tissue, reducing the risk of neck scars and other complications. The procedure is considered safe for some patients, particularly those with larger thyroids or known cancers.
New studies on Fukushima's aftermath might uncover more accurate estimates of health consequences of nuclear power plant accidents, including thyroid cancer risks for children and young adults. The authors also highlight the psychological burden of nuclear disasters on those affected.
A long-term study found that children exposed to head and neck radiation have a lifelong increased risk of developing thyroid cancer. The study, published in Radiation Research, indicates that even low doses of radiation can increase the risk, and that this risk continues for at least 57 years.
The AAO-HNSF miniseminars discussed presbycusis, a growing concern for older adults with hearing loss. The researchers also presented new medullary thyroid cancer guidelines, highlighting the need for familiarity with unique diagnostic and treatment paradigms. Additionally, safety concerns in pediatric ambulatory surgery were emphasized.
A phase 2 trial found that pazopanib, an antiangiogenetic drug, significantly improved outcomes for patients with advanced differentiated thyroid cancers. Approximately 49% of patients experienced a partial response, with two-thirds likely to have a lasting response over 1 year.
Researchers at Mayo Clinic found that pazopanib significantly decreased progression rate in patients with metastatic, rapidly progressive differentiated thyroid cancers. The median progression-free survival time was 11.7 months, with an overall survival rate of 81 percent at one year.
Studies show molecular imaging improves evaluation and treatment planning for various cancers, including thyroid cancer, lymphoma, and non-small cell lung cancer. The technique allows doctors to identify disease severity and extent, providing personalized care and adjusting treatment plans accordingly.
The Mayo Clinic team created four new ATC cell lines with distinct molecular mutations, which will aid in testing new treatments and potentially lead to improved survival rates. The researchers also found that these cell lines reactivate a tumor suppressor gene called RhoB, leading to growth suppression.
A new study by endocrinologists at the University at Buffalo has shown that Vietnam veterans exposed to Agent Orange have significantly more Graves' disease, a thyroid disorder. The autoimmune disease was three times more prevalent among veterans who encountered the dioxin-containing chemical.
Researchers at Mayo Clinic have found a new aggressive treatment approach for anaplastic thyroid carcinoma to be highly effective, resulting in 70% one-year survival rate. The treatment combines surgery, intensity modulated radiation therapy, and chemotherapy, and is being tested in a nationwide clinical trial.
A recent study found that most patients with localized papillary thyroid cancer can expect favorable outcomes without treatment. The 20-year survival rate for these patients is estimated to be around 97%, similar to those who received treatment. Clinicians and patients can feel comfortable considering observation as an option.
Researchers discovered specific PTEN mutations linked to distinct kinds of cancer in organs targeted by Cowden syndrome. The study suggests that testing for these mutations could predict cancer severity in patients with the syndrome.
A combined PET-CT scan can accurately detect cancer in patients with neurologic symptoms more effectively than other tests. The study found that PET-CT detected abnormalities suggestive of cancer in 39% of patients, leading to early treatment and improved outcomes for 12 patients.
The American Thyroid Association has released new guidelines for managing thyroid nodules and thyroid cancer, focusing on clinical evaluation, fine-needle biopsy, and surgical management. The revised guidelines aim to provide a framework for the care of patients with nodular thyroid disease and thyroid cancer.
Residents of the volcanic area of Mt. Etna in Catania had a more than two times higher incidence of papillary thyroid cancer compared to those elsewhere on the island. The tumors from patients in this region frequently carried the BRAF V600E gene mutation, associated with aggressive thyroid cancer.
A Dutch study found that only 8.2% of fatigue patients received a diagnosis of severe illness, with musculoskeletal problems and psychological issues being the most common diagnoses. The study highlights the complexity of fatigue as a symptom of underlying specific disease.
A study examined thyroid surgery complications in patients aged 21-65. Results showed similar rates of complications between younger and older patients, with higher readmission rates due to hypocalcemia in the elderly group.
A new robot-assisted endoscopic technique successfully treated 200 consecutive patients with thyroid cancer, offering safer and easier operations with minimal scarring. The minimally invasive procedure uses the da Vinci Surgical System to remove part or all of the thyroid gland with less risk of complications.
Researchers found that ultrasound outperforms symptom analysis in detecting ovarian cancer, with TVS performing better for malignancies. Racial disparities in colorectal cancer survival dissipate after adjusting for demographic and clinical factors. Thyroid cancer incidence increases across all tumor sizes, suggesting screening is not ...
The American Thyroid Association has developed comprehensive guidelines for diagnosing, treating, and monitoring patients with Medullary Thyroid Carcinoma (MTC), an uncommon form of thyroid cancer. The guidelines cover a range of clinical topics and propose directions for future research.
Researchers at Mayo Clinic found that pazopanib stops new blood vessel growth, slowing aggressive differentiated thyroid cancer. The treatment showed promising results in about two-thirds of patients with fast-growing cancers that had spread to lungs and other organs.
A study at the University of California San Francisco Medical Center found certain ultrasound features indicative of cancer, allowing for non-invasive management. Microcalcifications, taller-than-wide shape, and hypoechogenicity were identified as high-risk features.
Patients with a history of radiation exposure are more likely to develop aggressive thyroid cancer and experience worse clinical outcomes. The study found that radiation-exposed patients were more likely to undergo total or near-total thyroidectomy, have distant metastases, and die from the disease.
Researchers at Mayo Clinic have found that the experimental drug RS5444 turns on the RhoB tumor suppressor gene in cancer cells, inhibiting cell growth and blocking tumor growth. This finding suggests that other cancers may respond to this therapy, offering new hope for deadly anaplastic thyroid cancer treatment.
Researchers developed a hybrid SPECT-CT camera to accurately distinguish cancerous cells from healthy tissue in regional lymph nodes. This technology enables earlier detection and individualized treatment of thyroid cancer.
Mortality rates for most Canadian cancers are declining, while others are increasing, including liver and lung cancer. Research shows that at least half of all cancers are preventable, emphasizing the need for effective cancer control measures.
Preliminary trials of a new multi-kinase inhibitor, XL184, have indicated impressive tumour shrinkage activity in patients with advanced medullary thyroid cancer. The overall disease control rate was 84% in the 25 patients who have been followed for at least three months.
Researchers discovered a link between atomic bomb exposure and adult-onset papillary thyroid cancer, with a higher risk among younger people. The study found that radiation dose, age at the time of bombing, and elapsed time since exposure were independently associated with the development of the disease.
A clinical trial found that motesanib diphosphate, a VEGF inhibitor, slowed disease progression in some patients with metastatic thyroid cancer. The study also identified a genetic mutation associated with better response rates, offering potential for personalized therapy.
A new test using galectin-3 may help identify benign thyroid nodules, reducing the need for surgery. The test showed high sensitivity and specificity, with a positive predictive value of 82%.
A 12-year study found a significant increase in differentiated thyroid cancer cases, with small subclinical tumours accounting for the rise. Advances in medical imaging are thought to be responsible for the increased detection rate, rather than a change in disease patterns.
A specific gene mutation, BRAF V600E, is associated with increased risk of recurrence and death in thyroid cancer patients. The mutation can help guide treatment options and follow-up care, including aggressive surgery and radioiodine therapy.
Researchers found that percutaneous ethanol injection (PEI) significantly reduces tumor volume and alleviates symptoms in patients with radioiodine-ineffective bone metastasis from thyroid cancer. PEI's effectiveness was also linked to improved quality of life for selected patients.
Axitinib produced tumor regression or stable disease in almost 75% of patients with advanced thyroid cancer, according to a phase-2 trial. The study also found that axitinib prevented tumor growth and had a favorable side effect profile.
A study found that hepatitis C virus (HCV) infection increases the risk of non-Hodgkin lymphoma by 20-30% and Waldenström macroglobulinemia by nearly three-fold. HCV is also linked to an increased risk of nonmalignant plasma cell disorders.
A new study found that hairy cell leukemia survivors have an increased risk of developing certain cancers, including Hodgkin lymphoma and thyroid cancer. Meanwhile, a new test may be able to identify patients with a specific type of gene mutation that indicates an inherited form of colorectal cancer or potential response to certain drugs.
AkaRx has licensed the tetrac patents for treating thyroid cancer, developing AKR-201 to suppress TSH production. The drug aims to reduce side effects of hyperthyroidism in patients with thyroid cancer
Researchers at Queen's University have uncovered molecular mechanisms of a cancer-causing protein linked to thyroid cancer, paving the way for new treatments and potential prevention methods. The study provides valuable tools for targeting specific actions of the protein, which may aid in the development of anticancer therapies.
Researchers discovered that caveolin-3 inhibits myostatin signaling, preventing muscle wasting. Additionally, elevated PTTG1 levels triggered mitotic mischief, causing aneuploidy in thyroid cancer cells. Understanding these mechanisms can lead to potential therapies for muscular dystrophy and thyroid cancer.
A study published in the Journal of the National Cancer Institute found that exposure to radioactive iodine after Chornobyl increases the risk of thyroid cancer in children and adolescents. Researchers estimate that 75% of thyroid cancer cases could have been avoided without radiation, highlighting a substantial contribution of radioac...
A study found that exposure to radioactive iodine after the Chornobyl accident significantly increases the risk of thyroid cancer in children and adolescents. The researchers estimate that 75% of these cases could have been avoided without radiation exposure.
A study found a significant increase in US thyroid cancer incidence from 1973-2002, largely attributed to improved early detection methods. The rise in papillary thyroid cancer was primarily due to increased detection of small cancers.
Researchers have created a new model to examine the process by which tumor cells develop an angiogenic phenotype, enabling them to grow rapidly. The study found that non-angiogenic tumor cells can switch to angiogenesis after several months, and that this switch is crucial for tumor growth and metastasis.
Researchers have discovered a new treatment option for thyroid cancer that allows patients to continue their thyroid hormone replacement therapy while undergoing radioiodine treatment, reducing unpleasant side effects. This breakthrough could improve the overall quality of life for thyroid cancer patients during treatment.
A new study has linked a specific gene mutation to poorer outcomes and increased recurrence of papillary thyroid cancer (PTC). The discovery provides a molecular marker to assess risk for patients with PTC, which is the most common type of thyroid cancer.
Researchers have identified 23 microRNAs that are significantly altered in the cancerous tissue compared to normal samples, with three miRs dramatically overexpressed and forming a signature that predicts the presence of malignant tissue. The study provides evidence for the regulatory role of microRNA in thyroid cancer development.
A study of Chernobyl children with thyroid cancer found no association between ret rearrangement and radiation exposure. Instead, the age of diagnosis may be a significant factor in understanding the molecular biology of thyroid cancer.
Researchers developed a new test for thyroid cancer that can detect recurrence up to three years before symptoms appear. The test measures thyroglobulin levels after injecting patients with Thyrogen, allowing for earlier detection of the disease.
A case-control study found a strong dose-response relationship between radiation dose and thyroid cancer risk, with iodine-deficient areas showing three times the risk. Stable iodine supplementation was associated with one-third the risk of radiation-related thyroid cancer compared to no supplementation.
A new study by Ohio State University researchers may lead to a test that prevents unnecessary thyroid gland removal in people with follicular adenoma. The study identified three genes, cyclin D2, PCSK2, and PLAB, which show distinct activity levels between noncancerous and cancerous thyroid conditions.
Researchers found that women with primary hypothyroidism had a 61 percent lower risk of developing invasive breast cancer and those newly diagnosed were 57 percent less likely to have the condition. Women with both conditions tended to be older when diagnosed with a less aggressive, indolent disease.